Genmab A/S (GMAB) is breaking out on Friday, last changing hands at $43.51 on the NASDAQ. That is a $3.51 gain from the prior close of $40.00 and pushes the stock into fresh territory. The move carries shares roughly 8.3% above the previous 52-week high of $40.17, set on October 5, 2026, and about 84.2% above the 52-week low of $23.62. A stock that has nearly doubled off its lows is now pressing past its old ceiling, and that says a great deal about how quickly the market is rerating this name.
Volume is running at roughly 8.15 million shares against a 90-day average of about 2.73 million, close to three times normal turnover. Buyers are moving with conviction on this session.
Why Genmab A/S Price is Moving Higher
The catalyst is clear and company-specific. On October 23, Genmab announced that its Phase 3 RAINFOL-02 trial of investigational Rina-S (rinatabart sesutecan) met both its primary progression-free survival goal and a key overall survival goal in platinum-resistant ovarian cancer. Among 584 patients, Rina-S cut the risk of disease progression or death by 71% compared with chemotherapy, with a hazard ratio of 0.29 and p<0.0001. In the 492-patient primary analysis set, the reduction was 67%. The company also reported a 57% lower risk of death in the overall trial population, with a hazard ratio of 0.43 and p<0.0001. The safety profile was consistent with prior experience, and no new safety signals emerged.
The overall survival result is what turns a good readout into a stock-moving one. Delaying progression is meaningful. Showing that patients live longer in a hard-to-treat setting like platinum-resistant ovarian cancer materially de-risks the program and strengthens Rina-S's case as a future standard of care. Genmab said it plans to discuss next steps with regulators worldwide and will submit the data for presentation at a future medical meeting. Management has also scheduled an investor update for October 28 at 5:00 p.m. CET, which gives the market a near-term event to sharpen its view of the commercial opportunity.
The gain stands out even more against the rest of the peer group. Merck & Co., Inc. (MRK) slipped 1.66% and Regeneron Pharmaceuticals, Inc. (REGN) fell 1.44% on the session, and rival Corcept Therapeutics (CORT) dropped 11%. That makes Genmab's advance a story about Genmab rather than the sector. The data also lands on a business that is already accelerating. Revenue reached $1.16 billion in the quarter ended June 30, 2026, up 29.5% from $896.00 million in the March quarter, and trailing revenue growth stands at 24.86%. With trailing EPS of $6.24 and a forward P/E of just 6.41, investors are getting late-stage pipeline upside at a valuation that still looks modest even after today's gain.
What is the Genmab A/S Rating - Should I Buy?
Weiss Ratings assigns GMAB a C+ rating. The rating was upgraded on 9/1/2026. Current recommendation is Hold. The September upgrade came before today's Phase 3 news. That means the rating already reflected improving fundamentals, and the RAINFOL-02 result adds a pipeline catalyst on top of a business that was trending in the right direction.
The strongest part of the profile is the balance sheet. Genmab is rated Excellent on the Solvency Index, which reflects a company that can fund global regulatory filings for Rina-S, plus continued development across epcoritamab and its solid tumor programs, without leaning on dilutive financing. The Good rating on the Efficiency Index shows the same strength from another angle. Royalty income from partnered blockbusters like DARZALEX flows through to earnings, which is how a company of this size supports $6.24 in trailing EPS. Shareholders have also been rewarded. The Good rating on the Total Return Index is backed by a run from a $23.62 low to a new high above $43, and today's breakout extends that record.
Where the picture becomes more nuanced is in the Growth Index and the Volatility Index. Genmab is rated Fair on growth despite 24.86% revenue growth and a 29.5% sequential jump to $1.16 billion. That rating suggests Weiss's broader measure of growth is not yet convinced the acceleration is durable, and the uneven move from $896.00 million to $1.16 billion between quarters supports that caution. The Weak Volatility Index reflects how sharply this stock can reprice on clinical news. Today's 8.8% jump on the Rina-S data is a favorable example, but the same sensitivity cuts both ways when trial readouts disappoint. These two dimensions are what keep the overall rating at C+ instead of moving into Buy territory.
Within the Health Care sector, Genmab ranks ahead of Merck & Co., Inc. (MRK, C), Gilead Sciences, Inc. (GILD, C), and Pfizer Inc. (PFE, C). That edge over some of the sector's largest names reflects Genmab's combination of balance sheet strength, efficient royalty economics, and stronger recent returns.
About Genmab A/S
Genmab A/S (GMAB) is a Health Care company founded in 1998 and headquartered in Copenhagen, Denmark. The company develops antibody-based medicines for cancer and other serious diseases. Its own commercial portfolio includes EPKINLY and TEPKINLY for adults with relapsed or refractory diffuse large B-cell lymphoma, large B-cell lymphoma, and follicular lymphoma. It also markets Tivdak for recurrent or metastatic cervical cancer that has progressed on or after chemotherapy. Epcoritamab is being developed further across first-line lymphoma, chronic lymphocytic leukemia, Richter's syndrome, and pediatric B-cell cancers. The broader pipeline includes rinatabart sesutecan for platinum-resistant ovarian cancer and other solid tumors, acasunlimab for non-small cell lung cancer, and early-stage candidates such as GEN1059, GEN1055, GEN1057, and GEN1286.
What sets Genmab apart is the reach of its antibody technology into partnered products. DARZALEX and DARZALEX FASPRO for multiple myeloma and light-chain amyloidosis are central to the company's economics. Its participation also extends to RYBREVANT for non-small cell lung cancer, TECVAYLI and TALVEY for multiple myeloma, Kesimpta for relapsing multiple sclerosis, and TEPEZZA for thyroid eye disease. Partnered development continues with amivantamab in head and neck and colorectal cancers, amlenetug for multiple system atrophy, inclacumab for sickle cell vaso-occlusive crises, and Mim8 for hemophilia A.
This partnership model is a durable competitive advantage. Genmab's collaborators include AbbVie, Pfizer, BioNTech, Johnson & Johnson, Bristol Myers Squibb, Lundbeck, Amgen, Novo Nordisk, and argenx. That network lets Genmab capture value from global commercial infrastructure it does not have to build itself. Meanwhile, the company is steadily expanding its wholly owned franchise, with Rina-S and epcoritamab as its main growth drivers.
Investor Outlook
Genmab A/S (GMAB) carries a Weiss Rating of C+ (Hold), and today's Phase 3 overall survival result gives the stock a fresh, fundamentally grounded catalyst as it breaks above its prior high. Investors should watch the October 28 investor update for detail on Rina-S's regulatory path and commercial potential, along with upcoming quarterly results to see whether revenue growth of 24.86% continues. See full rankings of all C+ rated Health Care stocks inside the Weiss Stock Screener.
--